A special symposium session, intended to highlight therapeutic
advances, will focus on Tumor Treating Fields as a fourth modality in
cancer treatment
The volume of Tumor Treating Fields presentations marks a record
number of abstracts for Novocure at this conference
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor
Treating Fields at the American Association for Cancer Research (AACR)
Annual Meeting 2019, March 29 through April 3, in Atlanta. For the first
time at this conference, a symposium session on Tumor Treating Fields
also will be held.
The symposium session titled, “Tumor Treating Fields: A Fourth Modality
in Cancer Treatment,” will be chaired by Dr. Roger Stupp, Director of
Strategic Initiatives at Robert H. Lurie Comprehensive Cancer Center of
Northwestern University in Chicago. Presentation topics include
“Identification of a new mechanism for how Tumor Treating Fields affect
tumor cells” and “TTFields: From bench to bedside.” Presentation topics
will be followed by multiple discussion sessions.
The volume of Tumor Treating Fields presentations marks a record number
of abstracts for Novocure at this conference. Highlights include an oral
presentation on using transducer array layouts to optimize the treatment
of multiple brain metastases with Tumor Treating Fields and results from
a pilot study of Tumor Treating Fields combined with radiotherapy for
newly diagnosed glioblastoma.
“The presence of Tumor Treating Fields at the AACR Annual Meeting has
grown substantially over the last five years,” said Dr. Uri Weinberg,
Novocure’s Vice President of Clinical Development. “The AACR Annual
Meeting is one of the most important gatherings of cancer researchers
and clinicians throughout the world. We are honored to be a part of this
invaluable exchange of scientific information and proud of the
increasing focus on Tumor Treating Fields at this meeting.”
Symposium Session
Tumor Treating Fields: A Fourth Modality in Cancer Treatment
1 to 2:45 p.m. EDT April 2
Oral presentation
(Abstract #: 4450) Novel transducer array layouts to optimize the
treatment of multiple brain metastases with tumor treating fields. O.
Yesharim. 3 to 5 p.m. EDT April 2.
Poster presentations
(Abstract #: 688) Safety and efficacy of TTFields delivery to the lungs:
A computational study. H. Hershkovich. 1 to 5 p.m. EDT March 31.
(Session: Bioinformatics and Systems Biology; Convergence Science for
Therapeutics and Precision Medicine; poster board #: 21)
(Abstract #: 691) Simulating TTFields-induced temperature changes within
a patient’s brain – a proof of concept study. A. Naveh. 1 to 5 p.m. EDT
March 31. (Session: Bioinformatics and Systems Biology; Convergence
Science for Therapeutics and Precision Medicine; poster board #: 24)
(Abstract #: 692) Treating spinal cord metastases with tumor treating
fields. O. Yesharim. 1 to 5 p.m. EDT March 31. (Session: Bioinformatics
and Systems Biology; Convergence Science for Therapeutics and Precision
Medicine; poster board #:25)
(Abstract #: 689) Heating of head tissues during TTFields therapy: a
computational study. N. Gentilal. 1 to 5 p.m. EDT March 31. (Session:
Bioinformatics and Systems Biology; Convergence Science for Therapeutics
and Precision Medicine; poster board #: 22)
(Abstract #: 4430) Simulating delivery of TTFields to the infratentorium
in patients with brainstem gliomas. 1 to 5 p.m. EDT March 31. (Session:
Molecular and Cellular Biology / Genetics; Targeting the Cell Cycle:
Development of Preclinical Models and Therapeutic Targets; poster board
#: 24)
(Abstract #: 4430) Numerical simulation of tumor treating fields effects
on cell structures: Mechanism and signaling pathway candidates. 1 to 5
p.m. EDT April 2. (Session: Tumor Biology; Radiation Tissue Tolerance,
Immunity, and in Vivo Effects of Radiation; poster board #: 2)
(Abstract #: 3724) Molecular mechanisms of TTField action determined by
measurements and modelling of electro-conductive properties of
microtubules. A. Kalra. 1 to 5 p.m. EDT April 2. (Session: Tumor
Biology; Radiation Tissue Tolerance, Immunity, and in Vivo Effects of
Radiation; poster board #: 1)
(Abstract #:4871) Comparative analysis of tumor treating fields using
conventional versus alternative array placement for posterior fossa
Glioblastoma. E. Lok. 8 a.m. to 12 p.m. EDT April 3. (Session: Clinical
Research; Advances in Radiation Therapy / Surgical Oncology; poster
board #: 15)
(Abstract #: 252) Tumor treating fields (TTFields) affect blood brain
barrier (BBB) integrity in vitro and in vivo. A. Kessler. 1 to 5 p.m.
EDT March 31. (Session: Experimental and Molecular Therapeutics; Brain
Cancers and Neuroblastoma; poster board #: 15)
(Abstract #: 250) Tumor treating fields increases membrane permeability
in glioblastoma cells. E. Chang. 1 to 5 p.m. EDT March 31. (Session:
Experimental and Molecular Therapeutics; Brain Cancers and
Neuroblastoma; poster board #: 13)
(Abstract #: 239) Aurora kinase inhibition to enhance Tumor Treating
Fields efficacy in glioblastoma treatment. P. Bartmann. 1 to 5 p.m. EDT
March 31. (Session: Experimental and Molecular Therapeutics; Brain
Cancers and Neuroblastoma; poster board #: 2)
(Abstract #: 307) The combined treatment of 150 kHz Tumor Treating
Fields (TTFields) and cisplatin or pemetrexed inhibit mesothelioma cells
in vitro. M. Munster. 1 to 5 p.m. EDT March 31. (Session: Experimental
and Molecular Therapeutics; Brain Cancers and Neuroblastoma; poster
board #28)
(Abstract #: 306) The efficacy of the combined treatment of 150 KHz
tumor treating fields (TTFields) and Sorafenib in hepatocellular
carcinoma in vitro and in vivo. T. Voloshin. 1 to 5 p.m. EDT March 31.
(Session: Experimental and Molecular Therapeutics; Brain Cancers and
Neuroblastoma; poster board #27)
(Abstract #: 303) The efficacy of the combined treatment of 150 kHz
Tumor Treating Fields (TTFields) and FOLFOX in gastric cancer in vitro.
1 to 5 p.m. EDT March 31. (Session: Combination Approaches to Novel
Therapies; poster board #: 24)
(Abstract #: 1258) Pooled-analysis of response markers in cancer cell
lines treated with tumor treating fields. G. Shahaf. 8 a.m. to 12 p.m.
April 1. (Session: Experimental and Molecular Therapeutics;
Credentialing of Molecular Targets; poster board #: 19)
(Abstract #: 2168) Testing the electrical properties of different cell
lines using 3DEP reader and compare to TTFields response. M. Giladi. 1
to 5 p.m. April 1. (Session: Experimental and Molecular Therapeutics;
Credentialing of Molecular Targets; poster board #: 19)
(Abstract #: 2191) Reduced clonogenic potential of patient-derived lung
adenocarcinoma brain metastasis cells after in vitro application of
Tumor Treating Fields (TTFields). S. Michelhaugh. 1 to 5 p.m. EDT April
1. (Session: Experimental and Molecular Therapeutics; Credentialing of
Molecular Targets; poster board #: 13)
(Abstract #: 2192) Concurrent Tumor Treating Fields (TTFields) and
dexamethasone decrease proliferation and clonogenicity of
patient-derived glioblastoma cells in vitro. S. Michelhaugh. 1 to 5 p.m.
EDT April 1. (Session: Experimental and Molecular Therapeutics;
Credentialing of Molecular Targets; poster board #: 14)
(Abstract #: 2094) Prostaglandin E receptor 3 mediates resistance to
tumor treating fields in glioblastoma cells. D. Chen. 1 to 5 p.m. EDT
April 1. (Session: Experimental and Molecular Therapeutics; Drug
Resistance 3; poster board #: 1)
(Abstract #: 3280) TTFields induces immunogenic cell death and STING
pathway activation through cytoplasmic double-stranded DNA in
glioblastoma cells. D. Chen. 8 a.m. to 12 p.m. EDT April 2. (Session:
Immunology; Novel Immunomodulatory Agents 1; poster board #: 30)
(Abstract #: 3493) Tumor treating fields (TTFields) significantly alters
how tumor cells repair double stranded breaks using homeologous Alu
sequences. M. Morales. 8 a.m. to 12 p.m. EDT April 2. (Session: DNA
Damage and Repair 3; Molecular and Cellular Biology / Genetics; poster
board #: 4)
(Abstract #: 3939) Exploiting tumor treating fields induced
downregulation of BRCA1 pathway for novel combination therapies. N.
Karanam. 1 to 5 p.m. EDT April 2. (Session: Experimental and Molecular
Therapeutics; Preclinical Radiotherapeutics; poster board #: 20)
(Abstract #: 3954) Evaluating the compatibility of tumor treating
electric fields with key anti-tumoral immune functions. G. Diamant. 1 to
5 p.m. EDT April 2. (Session: Clinical Research; Immunomodulation by
Chemotherapy and Targeted Agents; poster board #: 10)
(Abstract #: 3961) Alternating electric fields (TTFields) induce
immunogenic cell death resulting in enhanced antitumor efficacy when
combined with anti-PD-1 therapy. T. Voloshin. (Session: Clinical
Research; Immunomodulation by Chemotherapy and Targeted Agents; poster
board #: 17)
(Abstract #: 4031) The dielectric properties of brain tumor tissue. M.
Proescholdt. 1 to 5 p.m. EDT April 2. (Session: Clinical Research; Tumor
Markers to Assess the Biology and Clinical Course of Cancer 2; poster
board #: 24)
(Abstract #: 4419) Cell cycle analysis during TTF to exploit novel
targets for increasing treatment efficacy. P. Slangen. 1 to 5 p.m. EDT
April 2. (Session: Molecular and Cellular Biology / Genetics; Targeting
the Cell Cycle: Development of Preclinical Models and Therapeutic
Targets; poster board #: 13)
(Abstract #: 3942) Animal studies evaluating the safety of Tumor
Treating Fields (TTFields) in the torso. S. Davidi. 1 to 5 p.m. EDT
April 2. (Session: Experimental and Molecular Therapeutics; Preclinical
Radiotherapeutics; poster board #: 23)
(Abstract #: 5271) Molecular imaging of pyruvate kinase M2 (PKM2) with
[18F]DASA-23 detects temozolomide- and tumor treating fields
(TTFields)-induced changes in glycolysis in glioblastoma. C. Patel. 8
a.m. to 12 p.m. EDT April 3. (Session: Molecular and Cellular Biology /
Genetics; Tracking Metabolic Profiles and Subtype-specific Metabolic
Interventions; poster board #: 14)
(Abstract #: 5156) In vitro application of tumor-treating fields to
suppress tunneling nanotubes in mesothelioma. A. Sarkari. 8 a.m. to 12
p.m. EDT April 3. (Session: Molecular and Cellular Biology / Genetics;
Cellular and Stromal Interactions of Tumor Cells; poster board #: 8)
(Abstract #: CT008) Tumor Treating Fields combined with radiotherapy and
temozolomide for newly diagnosed glioblastoma: Final results from a
pilot study. A. Hormigo. 8 a.m. to 12 p.m. EDT April 1. (Session: Phase
I Clinical Trials: Part 1; poster board #: 3)
(Abstract #: CT062) A Phase I study of the safety and immunogenicity of
personalized mutation-derived tumor vaccine and treatment fields in
patients with newly diagnosed glioblastoma. A. Hormigo. 8 a.m. to 12
p.m. EDT April 1. (Session: Phase I Clinical Trials: Part 2; poster
board #: 19)
(Abstract #: 1413) Using conventional imaging to predict water content
and electrical properties at 200 kHz in brain and GBM tumor tissues: a
feasibility study in three TTFields patients. C. Wenger. 8 a.m. to 12
p.m. April 1. (Session: Deep Learning; Clinical Research; poster board
#: 22)
(Abstract #: CT172) Phase III METIS study: Tumor Treating Fields (150
kHz) and radiosurgery for supra- and/or infratentorial brain metastases
(1-10) from non-small cell lung cancer (NSCLC). M. Mehta. 8 a.m. to 12
p.m. EDT April 2. (Session: Phase I-III Trials in Progress: Part 2;
poster board #: 16)
(Abstract #: CT175) HEPANOVA Phase 2 study design for advanced
hepatocellular carcinoma: tumor treating fields concomitant with
sorafenib. A. Grosu. 8 a.m. to 12 p.m. EDT April 2. (Session: Phase
I-III Trials in Progress: Part 2; poster board #: 19)
(Abstract #: CT174) Phase III INNOVATE study of tumor treating fields
(200 kHz) concomitant with weekly paclitaxel for platinum-resistant
ovarian cancer (ENGOT-ov50/BGOG study groups). I. Vergote. 8 a.m. to 12
p.m. EDT April 2. (Session: Phase I-III Trials in Progress: Part 2;
poster board #: 18)
(Abstract #: CT173) Tumor Treating Fields (150 kHz) concurrent with
standard of care treatment for stage 4 non-small cell lung cancer
(NSCLC) following platinum failure: The Phase III LUNAR study. U.
Weinberg. 8 a.m. to 12 p.m. EDT April 2. (Session: Phase I-III Trials in
Progress: Part 2; poster board #: 17)
(Abstract #: CT176) Phase III PANOVA study of tumor treating fields (150
kHz) in combination with nab-paclitaxel and gemcitabine for front-line
treatment of locally-advanced pancreatic adenocarcinoma (LAPC). U.
Weinberg. 8 a.m. to 12 p.m. EDT April 2. (Session: Phase I-III Trials in
Progress: Part 2; poster board #: 20)
(Abstract #: CT202) Safety of Tumor Treating Fields delivery to the
torso: Pooled analysis from TTFields clinical trials. G. Ceresoli. 1 to
5 p.m. EDT April 2. (Session: Phase II-III Clinical Trials: Part 2;
poster board #: 16)
(Abstract #: CT204) Increasing Tumor Treating Fields dose at the tumor
bed improves survival: Setting a framework for TTFields dosimetry based
on analysis of the EF-14 Phase III trial in newly diagnosed
glioblastoma. M. Ballo. 1 to 5 p.m. EDT April 2. (Session: Phase II-III
Clinical Trials: Part 2; poster board #: 18)
(Abstract #: CT201) Final results of Phase II STELLAR trial: TTFields
with chemotherapy in unresectable malignant pleural mesothelioma. G.
Ceresoli. 1 to 5 p.m. EDT April 2. (Session: Phase II-III Clinical
Trials: Part 2; poster board #: 15)
(Abstract #: CT203) Randomized Phase II trial of Tumor Treating Fields
plus radiation therapy plus temozolamide compared to radiation therapy
plus temozolomide in patients with newly diagnosed glioblastoma. R.
Grossman. 1 to 5 p.m. EDT April 2. (Session: Phase II-III Clinical
Trials: Part 2; poster board #: 17)
(Abstract #: CT205) Tumor Treating Fields alters progression patterns in
glioblastoma: An imaging analysis of the EF-14 Phase III trial. S.
Jeyapalan. 1 to 5 p.m. EDT April 2. (Session: Phase II-III Clinical
Trials: Part 2; poster board #: 19)
(Abstract #: LB-155) Adherence to tumor treating fields (TTFields) in
high-grade glioma patients – a single center experience. C. Hagemann. 8
a.m. to 12 p.m. EDT April 2. (Session: Science and Health Policy
2/Regulatory Science and Policy; poster board #: 13)
(Abstract #: LB-160) Glioblastoma and mesothelioma: Do estimates of
health state utilities compare in rare cancers treatable with tumor
treating fields? C. Proescholdt. 8 a.m. to 12 p.m. EDT April 2.
(Session: Science and Health Policy 2/Regulatory Science and Policy;
poster board #:18)
(Abstract #: LB-162) Treating elderly glioblastoma patients > 65 years
with TTFields – a cost-effectiveness perspective. G. Guzauskas. 8 a.m.
to 12 p.m. EDT April 2. (Session: Science and Health Policy 2/Regulatory
Science and Policy; poster board #: 20)
(Abstract #: LB-163 ) Comparing clinical value scores (NCCN, ASCO and
ESMO) for TTFields treatment in glioblastoma. J. Kelly. 8 a.m. to 12
p.m. EDT April 2. (Session: Science and Health Policy 2/Regulatory
Science and Policy; poster board #: 21)
(Abstract #: LB-161): Application of the ASCO and ESMO frameworks to
TTFields treatment of mesothelioma. J. Kelly. 8 a.m. to 12 p.m. EDT
April 2. (Session: Science and Health Policy 2/Regulatory Science and
Policy; poster board #: 18)
About Novocure
Novocure is a global oncology company working to extend survival in some
of the most aggressive forms of cancer by developing and commercializing
its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is
a cancer therapy that uses electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s commercialized
product is approved for the treatment of adult patients with
glioblastoma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in mesothelioma, brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver
cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory submission and approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify some
of these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions as well as more
specific risks and uncertainties facing Novocure such as those set forth
in its Annual Report on Form 10-K filed on February 28, 2019, with the
U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend to
update publicly any forward-looking statement, except as required by
law. Any forward-looking statements herein speak only as of the date
hereof. The Private Securities Litigation Reform Act of 1995 permits
this discussion.
Contacts
Media and Investors:
Ashley Cordova
acordova@novocure.com
212-767-7558